Search Results

Re-ROUTE Data Presented for Boston Scientific's OffRoad Re-Entry Catheter System

October 8, 2013—Boston Scientific Corporation (Natick, MA) announced that the company's OffRoad re-entry catheter system demonstrated excellent performance in facilitating the treatment of chronic total occlusions (CTOs) in the major arteries that supply blood to the legs.

Boston Scientific Launches OffRoad Re-Entry Catheter System

February 5, 2014—Boston Scientific Corporation (Natick, MA) announced the United States launch and first use of the OffRoad re-entry catheter system for the treatment of chronic total occlusions in the major arteries of the legs.  The company advised that the device received US Food and Drug Administration clearance in late 2013, after favorable results from the Re-ROUTE clinical trial. In the trial, investigators using the OffRoad system were successful in navigating challenging chronic total occlusions in 84.8% of the enrolled patients, exceeding the trial’s prespecified goals.

Data Presented on Biotronik's Passeo-18 Lux DCB and Pulsar-18 BMS

January 25, 2017—Biotronik announced that interim data on the efficacy of the company's dedicated lower limb intervention portfolio were presented during a scientific symposium at LINC 2017, the Leipzig Interventional Course in Leipzig, Germany.

Biotronik’s Dynetic-35 Iliac Stent to Be Evaluated in BIONETIC-I Study

September 27, 2021—Biotronik announced the beginning of enrollment in the BIONETIC-I study of the safety and efficacy of the company’s Dynetic-35 cobalt-chromium, balloon-expandable stent system for the treatment of atherosclerotic peripheral artery disease lesions in the iliac arteries.